These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 24015299)
1. HER2 as a promising target for cytotoxicity T cells in human melanoma therapy. Ma J; Han H; Liu D; Li W; Feng H; Xue X; Wu X; Niu G; Zhang G; Zhao Y; Liu C; Tao H; Gao B PLoS One; 2013; 8(8):e73261. PubMed ID: 24015299 [TBL] [Abstract][Full Text] [Related]
2. Bispecific anti-CD3 x anti-HER2 antibody mediates T cell cytolytic activity to HER2-positive colorectal cancer in vitro and in vivo. Han H; Ma J; Zhang K; Li W; Liu C; Zhang Y; Zhang G; Ma P; Wang L; Zhang G; Tao H; Gao B Int J Oncol; 2014 Dec; 45(6):2446-54. PubMed ID: 25242665 [TBL] [Abstract][Full Text] [Related]
3. Anti-CD3 x anti-HER2 bispecific antibody effectively redirects armed T cells to inhibit tumor development and growth in hormone-refractory prostate cancer-bearing severe combined immunodeficient beige mice. Davol PA; Smith JA; Kouttab N; Elfenbein GJ; Lum LG Clin Prostate Cancer; 2004 Sep; 3(2):112-21. PubMed ID: 15479495 [TBL] [Abstract][Full Text] [Related]
4. Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation. Grabert RC; Cousens LP; Smith JA; Olson S; Gall J; Young WB; Davol PA; Lum LG Clin Cancer Res; 2006 Jan; 12(2):569-76. PubMed ID: 16428502 [TBL] [Abstract][Full Text] [Related]
5. Bispecific anti-CD3 x anti-B7-H3 antibody mediates T cell cytotoxic ability to human melanoma in vitro and in vivo. Ma J; Shang T; Ma P; Sun X; Zhao J; Sun X; Zhang M Invest New Drugs; 2019 Oct; 37(5):1036-1043. PubMed ID: 30706335 [TBL] [Abstract][Full Text] [Related]
6. Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies. Zitron IM; Thakur A; Norkina O; Barger GR; Lum LG; Mittal S BMC Cancer; 2013 Feb; 13():83. PubMed ID: 23433400 [TBL] [Abstract][Full Text] [Related]
7. Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors. Sen M; Wankowski DM; Garlie NK; Siebenlist RE; Van Epps D; LeFever AV; Lum LG J Hematother Stem Cell Res; 2001 Apr; 10(2):247-60. PubMed ID: 11359672 [TBL] [Abstract][Full Text] [Related]
8. Targeting bladder cancer using activated T cells armed with bispecific antibodies. Ma J; Ge J; Xue X; Xiu W; Ma P; Sun X; Zhang M Oncol Rep; 2018 Mar; 39(3):1245-1252. PubMed ID: 29328392 [TBL] [Abstract][Full Text] [Related]
9. Preclinical studies comparing different bispecific antibodies for redirecting T cell cytotoxicity to extracellular antigens on prostate carcinomas. Lum HE; Miller M; Davol PA; Grabert RC; Davis JB; Lum LG Anticancer Res; 2005; 25(1A):43-52. PubMed ID: 15816517 [TBL] [Abstract][Full Text] [Related]
10. Enhanced cytotoxicity against solid tumors by bispecific antibody-armed CD19 CAR T cells: a proof-of-concept study. Thakur A; Scholler J; Schalk DL; June CH; Lum LG J Cancer Res Clin Oncol; 2020 Aug; 146(8):2007-2016. PubMed ID: 32449004 [TBL] [Abstract][Full Text] [Related]
11. B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy. Ma J; Ma P; Zhao C; Xue X; Han H; Liu C; Tao H; Xiu W; Cai J; Zhang M Oncotarget; 2016 May; 7(20):29480-91. PubMed ID: 27121051 [TBL] [Abstract][Full Text] [Related]
13. Targeting immunotherapy for bladder cancer using anti-CD3× B7-H3 bispecific antibody. Ma W; Ma J; Ma P; Lei T; Zhao M; Zhang M Cancer Med; 2018 Oct; 7(10):5167-5177. PubMed ID: 30253078 [TBL] [Abstract][Full Text] [Related]
14. A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells. Yu S; Zhang J; Yan Y; Yao X; Fang L; Xiong H; Liu Y; Chu Q; Zhou P; Wu K J Exp Clin Cancer Res; 2019 Aug; 38(1):355. PubMed ID: 31412896 [TBL] [Abstract][Full Text] [Related]
15. Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model. Reusch U; Sundaram M; Davol PA; Olson SD; Davis JB; Demel K; Nissim J; Rathore R; Liu PY; Lum LG Clin Cancer Res; 2006 Jan; 12(1):183-90. PubMed ID: 16397041 [TBL] [Abstract][Full Text] [Related]
16. Activated T cells from umbilical cord blood armed with anti-CD3 × anti-CD20 bispecific antibody mediate specific cytotoxicity against CD20+ targets with minimal allogeneic reactivity: a strategy for providing antitumor effects after cord blood transplants. Thakur A; Sorenson C; Norkina O; Schalk D; Ratanatharathorn V; Lum LG Transfusion; 2012 Jan; 52(1):63-75. PubMed ID: 21745212 [TBL] [Abstract][Full Text] [Related]
17. Anti-CD3 x EGFR bispecific antibody redirects cytokine-induced killer cells to glioblastoma in vitro and in vivo. Ma P; He Q; Li W; Li X; Han H; Jin M; Liu C; Tao H; Ma J; Gao B Oncol Rep; 2015 Nov; 34(5):2567-75. PubMed ID: 26323605 [TBL] [Abstract][Full Text] [Related]
18. The bispecific anti-CD3 × anti-CD155 antibody mediates T cell immunotherapy for human prostate cancer. Zhao H; Ma J; Lei T; Ma W; Zhang M Invest New Drugs; 2019 Oct; 37(5):810-817. PubMed ID: 30374653 [TBL] [Abstract][Full Text] [Related]
19. Engineering high affinity humanized anti-p185HER2/anti-CD3 bispecific F(ab')2 for efficient lysis of p185HER2 overexpressing tumor cells. Zhu Z; Lewis GD; Carter P Int J Cancer; 1995 Jul; 62(3):319-24. PubMed ID: 7628874 [TBL] [Abstract][Full Text] [Related]
20. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro. Gall JM; Davol PA; Grabert RC; Deaver M; Lum LG Exp Hematol; 2005 Apr; 33(4):452-9. PubMed ID: 15781336 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]